Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05003960 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description shortened, about 25 wordsv6
  2. Study sites: 2 to 3v5
  3. Primary and study completion dates: Sep 2025 to Dec 1, 2027
    • Study sites: 1 to 2
    v4
  4. Start date changed from estimate of Feb 2022 to Jan 23, 2022
    • Study description expanded, about 25 words
    v3
  5. Start date: Sep 2021 to Feb 2022
    • Site contact updated
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Autism
Trial Details
NCT Number NCT05003960
Lead Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Conditions
(from sponsor)		 Autism
Related terms Autistic Disorder
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov